Eli Lilly and Company (NYSE:LLY) Trading Down 3.2% - Time to Sell?

Key Points

• Shares fell intraday by 3.2% to about $1,013 with volume slightly below average, amid headlines prompting profit-taking after large prior gains.
• Eli Lilly says it could launch oral obesity drug orforglipron in the U.S. as soon as Q2 if approved, a potential major revenue driver, but faces competitive pressure from Novo Nordisk’s manufacturing expansion.
• Analysts remain broadly bullish—consensus rating is "Moderate Buy" with an average price target near $1,229.59—backed by a recent earnings beat (revenue up 42.6%) and FY2026 EPS guidance of 33.50–35.00.

Shares of Eli Lilly and Company (NYSE:LLY - Get Free Report) dropped 3.2% during trading on Monday . The stock traded as low as $1,013.00 and last traded at $1,017.9670. Approximately 3,079,183 shares were traded during mid-day trading, a decline of 9% from the average daily volume of 3,366,631 shares. The stock had previously closed at $1,051.99.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: The company said it is preparing to launch its oral obesity drug, orforglipron, in the U.S. as soon as Q2 if it receives FDA approval, which would add a major new revenue stream. Eli Lilly on track to launch oral obesity drug in second quarter, pending US approval
• Positive Sentiment: CHMP has backed expanding Olumiant’s use to adolescents with severe alopecia areata, which should widen EU market opportunity ahead of a formal EU approval decision. LLY Wins CHMP Nod for Olumiant's Expanded Use in Alopecia Areata
• Positive Sentiment: Institutional filings show continued accumulation by "smart money" during the recent pullback, indicating confidence from large holders. What Smart Money Loves About Lilly
• Positive Sentiment: Analyst coverage remains favorable overall (average recommendation around "Moderate Buy"), supporting sentiment that the company is broadly well-regarded by sell-side analysts. Eli Lilly and Company NYSE: LLY Receives Average Recommendation of "Moderate Buy" from Analysts
• Neutral Sentiment: Industry research notes Lilly as a large-cap name to retain as the pharma sector shows signs of recovery—supportive but not an immediate catalyst. 4 Large-Cap Pharma Stocks to Watch as Industry Recovery Gains Steam
• Neutral Sentiment: CEO David Ricks cautioned that AI isn’t yet solving complex biology/chemistry questions on its own—an operational comment that tempers hype but doesn’t change near-term commercial prospects. Tech giants see a cure for cancer in AI. But Eli Lilly’s CEO finds it ‘not particularly good’ at solving biology or chemistry problems
• Negative Sentiment: Competitor Novo Nordisk is expanding manufacturing in Ireland to bolster capacity for oral medicines, a move that strengthens Novo’s ability to meet demand and increases competitive pressure in the obesity/GLP-1 market. Why Novo Nordisk's Ireland expansion is key to fighting off Eli Lilly
• Negative Sentiment: Several commentary pieces highlight Lilly’s steep valuation after large recent gains and suggest investors consider cheaper alternatives—these narratives can amplify profit-taking and weigh on the stock. Up Over 400% in 5 Years, Is It Too Late to Invest in Eli Lilly Stock?
• Negative Sentiment: Articles urging investors to favor high-yield alternatives over Lilly emphasize the stock’s rich price multiples, which can discourage new entrants and cap upside near-term. Should You Forget Eli Lilly and Buy This Magnificent High-Yield Dividend Stock Instead?

Analyst Ratings Changes

Several analysts have recently issued reports on the company. TD Cowen increased their price objective on Eli Lilly and Company from $960.00 to $1,250.00 and gave the company a "buy" rating in a research note on Thursday, January 29th. Cantor Fitzgerald lifted their price target on Eli Lilly and Company from $985.00 to $1,205.00 and gave the stock an "overweight" rating in a research report on Thursday, February 5th. Leerink Partners increased their price objective on Eli Lilly and Company from $1,234.00 to $1,296.00 and gave the company an "outperform" rating in a report on Thursday, February 5th. Berenberg Bank upped their price target on shares of Eli Lilly and Company from $950.00 to $1,050.00 and gave the company a "hold" rating in a research report on Thursday, February 19th. Finally, Deutsche Bank Aktiengesellschaft increased their price target on shares of Eli Lilly and Company from $1,200.00 to $1,285.00 and gave the stock a "buy" rating in a research note on Monday, February 9th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and five have given a Hold rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $1,229.59.

Eli Lilly and Company Price Performance

The company has a market cap of $960.31 billion, a price-to-earnings ratio of 44.36, a PEG ratio of 1.22 and a beta of 0.40. The company's 50 day moving average price is $1,053.15 and its 200 day moving average price is $931.94. The company has a current ratio of 1.58, a quick ratio of 1.19 and a debt-to-equity ratio of 1.54.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $7.48 by $0.06. The business had revenue of $19.29 billion for the quarter, compared to analyst estimates of $17.85 billion. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The business's revenue was up 42.6% compared to the same quarter last year. During the same period in the previous year, the business posted $5.32 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Equities research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be issued a $1.73 dividend. The ex-dividend date of this dividend is Friday, February 13th. This represents a $6.92 annualized dividend and a dividend yield of 0.7%. This is an increase from Eli Lilly and Company's previous quarterly dividend of $1.50. Eli Lilly and Company's payout ratio is 30.15%.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Maryland Capital Advisors Inc. acquired a new position in Eli Lilly and Company during the fourth quarter worth about $25,000. Sumitomo Mitsui Financial Group Inc. acquired a new stake in shares of Eli Lilly and Company in the 2nd quarter worth approximately $27,000. Vermillion & White Wealth Management Group LLC increased its stake in Eli Lilly and Company by 84.2% in the 3rd quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company's stock valued at $27,000 after purchasing an additional 16 shares in the last quarter. Evolution Wealth Management Inc. purchased a new position in Eli Lilly and Company in the 2nd quarter valued at approximately $29,000. Finally, Steph & Co. raised its holdings in Eli Lilly and Company by 290.0% during the third quarter. Steph & Co. now owns 39 shares of the company's stock worth $30,000 after purchasing an additional 29 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.

About Eli Lilly and Company

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.